pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Obesity
drug
save

Obesity

Preclinicalupdated 6mo ago
by Metallomix Inc
Preclinical
community read0 votes

🐶 often sniffed alongside

top 8
  • tagObesity44 co-mentions · 34 sources
  • tagEndocrinology & Metabolism11 co-mentions · 11 sources
  • tagType 2 Diabetes8 co-mentions · 4 sources
  • tagOncology3 co-mentions · 2 sources
  • drugType 2 Diabetes3 co-mentions · 3 sources
  • druginsulin3 co-mentions · 3 sources
  • companyUniversity of Southern California2 co-mentions · 2 sources
  • tagMicrobiome2 co-mentions · 2 sources

indications

indications
Obesity

all catalysts(0)

nothing on the calendar yet

Trials studying Obesity

  • phase1A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risknot yet recruitingn=103
  • N/ADASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditionsrecruitingn=280
  • phase4Metabolic Surgery for Atrial Fibrillation Eliminationnot yet recruitingn=100
  • phase1An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.recruitingn=60
  • —DAta-driven personaLIzation of a digitAl Health Solution to Support Family Caregivers of Children With Chronic Conditionsrecruitingn=40
  • N/AThe Evira Study: Additional Support During Anti-Obesity Treatmentnot yet recruitingn=40
  • N/AEatit's Obesity Intervention: Effects on Weight, Eating Habits and Healthrecruitingn=93
  • N/AMothers and CareGivers Investing in Childrenenrolling by invitationn=165

News(10)

  • Lilly starts work on Pennsylvania obesity plant; ITM, AtomVie strike supply deal
    Lilly breaks ground in Pennsylvania: Eli Lilly has started construction on its $3.5 billion factory in Lehigh Valley, PA, which will manufacture obesity drugs including Lilly’s retatrutide. The sit…
    endpoints · 6h ago
  • STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
    Merck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technology
    stat · 9h ago
  • STAT+: NIH to move last group of its research chimps to a sanctuary
    The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.
    stat · 1d ago
  • ‘Selling and marketing snake oil’: The debate over compounded GLP-1s
    Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH confer…
    biopharma_dive · 1d ago
  • Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck
    LAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place. “I think the building’s the same, but that’s about it,” Cinca, Novo’s senior vice president of mark…
    endpoints · 1d ago
  • STAT+: FDA discloses reasons for rejecting Summit drug
    The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
    stat · 1d ago
  • STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
    The Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senate
    stat · 1d ago
  • Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
    The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
    biospace · 1d ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 1d ago
  • STAT+: Flagship opens biotech-creation outpost in the U.K.
    Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:
    stat · 2d ago
view all news mentions →
indication
Obesity
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?